Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 16;16(3):e0248729.
doi: 10.1371/journal.pone.0248729. eCollection 2021.

Accurate point-of-care serology tests for COVID-19

Charles F Schuler 4th  1   2 , Carmen Gherasim  3 , Kelly O'Shea  1   2 , David M Manthei  3 , Jesse Chen  1   4 , Don Giacherio  3 , Jonathan P Troost  5 , James L Baldwin  1   2 , James R Baker Jr  1   2   4
Affiliations

Accurate point-of-care serology tests for COVID-19

Charles F Schuler 4th et al. PLoS One. .

Abstract

Background: As COVID-19 vaccines become available, screening individuals for prior COVID-19 infection and vaccine response in point-of-care (POC) settings has renewed interest. We prospectively screened at-risk individuals for SARS-CoV-2 spike and nucleocapsid protein antibodies in a POC setting to determine if it was a feasible method to identify antibody from prior infection.

Methods: Three EUA-approved lateral flow antibody assays were performed on POC finger-stick blood and compared with serum and a CLIA nucleocapsid antibody immunoassay. Variables including antibody class, time since PCR, and the assay antigen used were evaluated.

Results: 512 subjects enrolled, of which 104 had a COVID-19 history and positive PCR. Only three PCR-positive subjects required hospitalization, with one requiring mechanical ventilation. The POC results correlated well with the immunoassay (93-97% sensitivity) and using serum did not improve the sensitivity or specificity.

Conclusions: Finger-stick, POC COVID-19 antibody testing was highly effective in identifying antibody resulting from prior infections in mildly symptomatic subjects. Using high-complexity serum immunoassays did not improve the screening outcome. Almost all individuals with COVID-19 infection produced detectable antibodies to the virus. POC antibody testing is useful as a screen for prior COVID-19 infection, and should be useful in assessing vaccine response.

PubMed Disclaimer

Conflict of interest statement

Dr. Schuler reported salary and other support from the Mary H. Weiser Food Allergy Center and the Taubman Innovation Institute at UM, as well as a UM COVID-19 Innovation Grant; he has also received sponsored project support from Healgen Scientific and Access Bio Inc. Dr. Troost was supported in part by the National Center for Advancing Translational Sciences (NCATS) for the Michigan Institute for Clinical and Health Research (UL1TR002240). Dr. Baldwin and Dr. Baker reported salary support from a UM COVID-19 Innovation Grant and sponsored project support from Healgen Scientific and Access Bio Inc. Dr. Gherasim, Dr. O’Shea, Dr. Manthei, Mr. Chen, and Dr. Giacherio reported no Competing Interests. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Symptoms of COVID PCR+ vs PCR- subjects.
Proportion of subjects with symptoms of potential COVID-19 infection among those with a positive PCR and those with a negative PCR. * p < 0.05, *** p < 0.001.
Fig 2
Fig 2. Results of serum testing for each LFA.
Proportion of known COVID-19 PCR positive subjects and known COVID-19 PCR negative or unknown PCR status with positive LFA result using serum for CareStart (A), Healgen (B) or Autobio (C). IgM status plotted against time from positive PCR to LFA test using serum for CareStart (D), Healgen (E), and Autobio (F). Note, D-F only include subjects with a known PCR-positive result. * p < 0.05. NS = not significant, p = 0.1076.
Fig 3
Fig 3. Results of finger-stick whole blood testing for each LFA.
Proportion of known COVID-19 PCR positive subjects and known COVID-19 PCR negative or unknown PCR status with positive LFA result using finger-stick blood in a point-of-care setting for CareStart (A), Healgen (B) or Autobio (C). IgM status plotted against time from positive PCR to LFA test using finger-stick blood in a point-of-care setting for CareStart (D), Healgen (E), and Autobio (F). Note, D-F only include subjects with a known PCR-positive result. ** p < 0.01. NS = not significant.
See this image and copyright information in PMC

References

    1. WHO. WHO Coronavirus Disease (COVID-19) Dashboard 2021 [updated 2/24/2021]. Available from: https://covid19.who.int/table.
    1. Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci. 2020;10:40. 10.1186/s13578-020-00404-4 - DOI - PMC - PubMed
    1. Brigger D, Horn MP, Pennington LF, Powell AE, Siegrist D, Weber B, et al.. Accuracy of serological testing for SARS-CoV-2 antibodies: first results of a large mixed-method evaluation study. Allergy. 2020. 10.1111/all.14608 - DOI - PMC - PubMed
    1. Jarrom D, Elston L, Washington J, Prettyjohns M, Cann K, Myles S, et al.. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2020. - PubMed
    1. Pavlova IP, Nair SS, Kyprianou N, Tewari AK. The Rapid Coronavirus Antibody Test: Can We Improve Accuracy? Front Med (Lausanne). 2020;7:569. 10.3389/fmed.2020.00569 - DOI - PMC - PubMed

Publication types